Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 5: 9.Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, et al. Plasma tau levels in Alz- heimer's disease. Alzheimers Res Ther. 2013 Jan 2; 5(2):9. doi: 10.1186/alzrt163 PMID: 23551972...
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare systems. Although AD can be identified and diagnosed by cerebrospinal fluid or neuroimaging biomarkers that concord with neuropathological evidence and ...
Figure 4. Plasma P-tau217 and NfL Levels as a Function of Age in the Autosomal-Dominant Alzheimer Disease Kindred (Cohort 3) View LargeDownload A and B, Plasma tau phosphorylated at threonine 217 (P-tau217) and neurofilament light chain (NfL) levels in PSEN1 E280A mutation carriers (orange...
Association Between Baseline Plasma Tau Level and 15-Month Change in Global and Domain-Specific Cognitiona,b View LargeDownload 1. Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther. 2013;5(2):9.PubMedGoogle ScholarCrossref 2. ...
To test whether plasma tau is altered in Alzheimer disease (AD) and whether it is related to changes in cognition, CSF biomarkers of AD pathology (including β-amyloid [Aβ] and tau), brain atrophy, and brain metabolism. This was a study of plasma tau in prospectively followed patients wit...
Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease Article Open access 10 May 2022 Downregulation of miR-181c-5p in Alzheimer’s disease weakens the response of microglia to Aβ phagocytosis Article Open access 20 May 2024 Introduction Alzheimer’s disease...
Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration could identify individuals at risk for cognitive decline in Alzheimer’s disease (AD). In blood, phosphorylated tau (p-tau) associates with Aβ pathophysiology but
P-TAU181 Assay See All Assays Recent Articles read article December 2, 2024 CTAD 2024 Fuels the Momentum in Advancing Alzheimer’s Disease Detection & Treatment with a Spotlight on Blood-Based Biomarkers read article October 3, 2024 Insights from ECTRIMS 2024: Exploring MS Biomark...
- 《Journal of Alzheimers Disease》 被引量: 111发表: 2009年 Plasma tau levels in Alzheimer's disease Introduction Efforts to find reliable blood biomarkers for Alzheimer's disease (AD) in a highly warranted clinical laboratory test have met with little suc... H Zetterberg,D Wilson,U ...
Angiostatin, an endogenous angiogenesis inhibitor generated by the proteolytic cleavage of plasminogen, was recently reported to contribute to the development of Alzheimer's disease (AD). However, whether there are pathological changes in angiostatin levels in individuals with AD dementia is unclear, and...